SBC Medical Group Reports Significant Q1 2026 Profit and Revenue Declines
SBC is trading near its 52-week low of $2.974 (11% above the low) on elevated volume (2.6× avg).
Summary
SBC Medical Group Holdings Inc. announced a significant drop in Q1 2026 net income and EPS, alongside a revenue decrease, raising concerns about its financial performance.
Key Events · Earnings and Guidance · SBC
-
Q1 2026 Revenue Decline
Total revenues decreased 9% year-over-year to $43 million for the first quarter ended March 31, 2026.
-
Profitability Plunge
Net income attributable to the company dropped 47% year-over-year to $11 million, with earnings per share (EPS) falling 48% to $0.11.
-
EBITDA Decrease
EBITDA declined 26% year-over-year to $18 million, with the EBITDA margin decreasing by 10 percentage points to 43%.
-
Management Commentary
CEO Yoshiyuki Aikawa attributed the revenue decline primarily to a strategic structural reform implemented in April 2025, involving a revision of the franchise fee structure, but stated core business performance remained solid.
Analysis · SBC · Industrial Applications And Services
SBC Medical Group Holdings Inc. reported a substantial year-over-year decline in its first-quarter 2026 financial results. Net income and earnings per share both fell by nearly 50%, while revenues decreased by 9%. This sharp reversal from the strong performance reported in the previous quarter raises concerns about the company's operational health, despite management attributing the revenue decline to a strategic structural reform.
At the time of this filing, SBC was trading at $3.30 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $331.3M. The 52-week trading range was $2.97 to $5.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.